-
Results for the Second Quarter and First Half 2023
Currency-neutral sales of own products were up 4.0% for the quarter and 2.5% for the first half. Operating profit (EBIT) for the quarter is up 13.1% and ended at MNOK 42.2, an EBIT margin of…
Read more -
Presentation of Medistim’s Q2 2023 Financial Results
The financials will be presented via a live webinar on Thursday, August 31st from 08:00-09:00 (CEST). Representatives for the company will be Kari Eian Krogstad (CEO), and Thomas Jakobsen (CFO). The recording will be made available on…
Read more -
Medistim announces partnership with ROMA-Women Trial
Medistim is pleased to announce its partnership with ROMA-Women, a groundbreaking cardiac surgery trial that is specifically focused on women. Historically, cardiovascular research and treatment protocols have primarily focused on men, leaving women underrepresented in…
Read more -
Results for the First Quarter 2023
NOK 82.1. The Vascular business segment continues the positive development and grows at 21.5% in NOK, currency neutral 8.8% growth. The Imaging products grow at 9.4% in NOK, currency neutral decline of 3.7%. Currency neutral…
Read more -
Presentation of Medistim’s Q1 2023 Financial Results
The financials will be presented via a live webinar on Tuesday, April 25th from 08:00-09:00 (CEST). Representatives for the company will be Kari Eian Krogstad (CEO), and Thomas Jakobsen (CFO). The recording will be made available on…
Read more -
Medistim is opening a direct sales office in China
More than 60,000 coronary bypass procedures are performed in China annually and the number is expected to continue to grow high single digit in the years to come. Today, about 70% of these procedures are…
Read more -
Annual Report 2022
Further supported by several high-quality symposia at the largest heart surgery conferences, we achieved 44 % growth in the imaging product portfolio in 2022. And while steadily penetrating the Cardiac bypass market, we also build…
Read more -
Medistim Expands Market Coverage in Canada by Going Direct
“We are excited to announce this strategic move that will strengthen our relationship with our customers in Canada and grow our business there,” – Medistim President and CEO Kari E. Krogstad
Read more -
Results for the Fourth Quarter and Preliminary Results for 2022
All major geographical regions drive sales growth. Currency-neutral sales increased by 21.6 % for the quarter and 11.9 % for the year. Currency-neutral sales of own products increase 24.6 % for the quarter and 14.0…
Read more -
Capital Markets Day
See the recording from Medistim's Capital Markets Day on March 21st where two international thought leaders, Professors John. D. Puskas and Pirkka Vikatmaa shared their insights on the future trends in Cardiac and Vascular Surgery…
Read more
PC: Hold CTRL and press + (plus) to enlarge or - (minus) to shrink.
MAC: Hold CMD and press + (plus) to enlarge or - (minus) to shrink.